Xeltis’ restorative coronary artery bypass graft (CABG), the XABG device, featured at two podium presentations at 2021 European Association for Cardio-Thoracic Surgery (EACTS) annual meeting. In a session about the science behind the future [...]

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living heart valves or blood vessels, have been published in peer-reviewed journal Acta Biomaterialia. Leading [...]

At Xeltis, we are marking World Heart Day thinking of all people born or leaving with heart disease. They give meaning to our working days and a greater purpose to our jobs. We have [...]

Remarkably positive one-year data from preclinical trials of Xeltis restorative coronary artery bypass graft (XABG) showed unprecedented patency for a synthetic small diameter graft device. The results showed that the device remained open to [...]

Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial results just published in the Journal of Biomedical Materials Research – Part A. The [...]

Xeltis has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To date, pediatric patients requiring right ventricular outflow tract (RVOT) reconstruction have been successfully implanted as part of the global, FDA-approved [...]

The Dutch State Secretary visited Xeltis today following the recent decision of the Government to provide funding to the RegMedXB partnership, of which Xeltis is one of the industrial partners. Minister Mona Keijzer met [...]

Xeltis CEO Eliane Schutte has been included in the Healthcare Technology Report’s list of 2021 Top 50 Healthcare Technology CEOs, one of only seven women featuring on the list. The Report’s list recognizes the [...]

Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative RestoreXTM technology. Published in the peer-reviewed journal Frontiers, the data included results from the [...]

Xeltis bio-restorative pulmonary heart valves and their clinical outcomes will feature at the upcoming Pediatric Device Innovators Forum organized by the U.S. Food and Drug Administration (FDA) in conjunction with five U.S. pediatric device [...]